LSTA

Lisata Therapeutics, Inc. (LSTA) Porter's 5 Forces Analysis (2026)

Invetso Score: 7.4/10 — Strong · Last Updated: 2026-09-01

Competitive Rivalry

Gross margin remains very high at 95%, suggesting some pricing power despite weak operating performance.

However, extreme SG&A at 116.44% of revenue and R&D at 48.81% of revenue indicate heavy competitive pressure and high cost intensity.

Revenue per share is only 0.01098, underscoring a very small revenue base relative to the company’s market value.

Threat Of New Entrants

The company’s current ratio of 3.69 and cash ratio of 3.50 provide liquidity that can help defend against near-term disruption.

But the business appears difficult to scale efficiently, with asset turnover of just 0.0091 and operating margins deeply negative.

High intangible-free tangible asset backing and a small enterprise value suggest limited barriers from capital intensity alone.

Bargaining Power Of Suppliers

No debt and a strong cash position reduce dependence on external financiers and improve flexibility with vendors.

Payables turnover is extremely low at 0.0060 and days payables outstanding are unusually high, implying the company may be stretching suppliers.

The lack of inventory and zero capex suggest a lean operating model, but supplier leverage remains hard to assess from the available data.

Bargaining Power Of Customers

Customer power appears high because the company’s revenue base is tiny relative to valuation, with price-to-sales at 152.08.

Receivables turnover of 0.5 and days sales outstanding of 730 indicate very slow collections and weak customer payment discipline.

Negative operating cash flow and deeply negative margins suggest customers can pressure pricing and terms.

Threat Of Substitutes

The company’s weak profitability and minimal revenue scale make it vulnerable to substitute offerings.

Negative returns on assets, equity, and invested capital indicate limited differentiation or switching-cost protection.

High gross margin is the main offset, but it has not translated into durable operating profitability.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →